Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

OBJECTIVES: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases I-III, tested ceftriaxone in ALS. Stage 1 determined the cerebrospinal fluid...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, James D., Shefner, Jeremy M., Conwit, Robin, Schoenfeld, David, Keroack, Myles, Felsenstein, Donna, Krivickas, Lisa, David, William S., Vriesendorp, Francine, Pestronk, Alan, Caress, James B., Katz, Jonathan, Simpson, Ericka, Rosenfeld, Jeffrey, Pascuzzi, Robert, Glass, Jonathan, Rezania, Kourosh, Rothstein, Jeffrey D., Greenblatt, David J., Cudkowicz, Merit E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629222/
https://www.ncbi.nlm.nih.gov/pubmed/23613806
http://dx.doi.org/10.1371/journal.pone.0061177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629222/
https://www.ncbi.nlm.nih.gov/pubmed/23613806
http://dx.doi.org/10.1371/journal.pone.0061177

Ejemplares similares